Abstract
KRAS mutations occur frequently in colorectal cancers (CRC) and predict lack of response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy. CRC BRAF muta-tions, most commonly at V600E, occur less than 10% of the time, and occur usually in KRAS wild-type tumors, and more frequently in microsatellite instable tumors. Concomitant KRAS and BRAF mutant CRCs are rare (occurring in 0.001%); BRAF mutations should not be routinely tested in patients with KRAS mutant tumors, unless the patients is participating in a clinical trial enriching for the presence of a KRAS or BRAF tumor. Clinical trials treating patients with either KRAS or BRAF mutant tumors should address eligibility ofpatients with concomitant KRAS and BRAF mutations.
Original language | English (US) |
---|---|
Pages (from-to) | 320-322 |
Number of pages | 3 |
Journal | Journal of Cancer |
Volume | 4 |
Issue number | 4 |
DOIs | |
State | Published - 2013 |
Keywords
- BRAF
- Concomitant KRAS
ASJC Scopus subject areas
- Oncology